Grufity logo
Grufity logo
ATAI

ATAI - ATA Inc-China Stock Price, Fair Value and News

$4.17+0.07 (+1.71%)
Delayed as of 24 Jun 2026, 04:00 pm ET

11/100

ATAI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

11/100

ATAI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ATAI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ATAI Price Action

Last 7 days

2.5%

Last 30 days

-3.5%

Last 90 days

17.8%

Trailing 12 Months

97.6%

ATAI RSI Chart

ATAI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ATAI Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-7.06

Price/Sales (Trailing)

3.5K

EV/EBITDA

-6.97

Price/Free Cashflow

-13.57

ATAI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ATAI Fundamentals

ATAI Revenue

Rev. Growth (Yr)

1.8K%

Rev. Growth (Qtr)

4.17%

ATAI Earnings

Earnings (TTM)

-154.2M

Earnings Growth (Yr)

-132.34%

Earnings Growth (Qtr)

-120.25%

ATAI Profitability

EBT Margin

-50036.69%

Return on Equity

-96.52%

Return on Assets

-64.29%

Free Cashflow Yield

-7.37%

ATAI Investor Care

Shares Dilution (1Y)

49.69%

Diluted EPS (TTM)

-0.81

Revenue & Growth

How ATA Inc-China generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2025----
2024-550.0K418.0K308.0K
2023252.0K271.0K334.0K314.0K
2022-13.7M6.9M233.0K
2021---20.4M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About ATA Inc-China

ATAI
ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.
 CEO
 WEBSITEatai.life
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES133

ATA Inc-China Frequently Asked Questions

ATAI is the stock ticker symbol of ATA Inc-China. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jun 24 2026, market cap of ATA Inc-China is 1.09 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Wed Jun 24 2026, ATAI's PE ratio (Price to Earnings) is -7.06 and Price to Sales (PS) ratio is 3.54 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATAI PE ratio will change depending on the future growth rate expectations of investors.